Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Matthews

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 24, 2020
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Plos One|June 14, 2014
Evaluation of common type 2 diabetes risk variants in a South Asian population of Sri Lankan descentNeelam Hassanali, N Maneka G De Silva, Neil Robertson, et al.
Diabetologia|May 15, 2020
Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literaturePrasad Katulanda, Harsha A Dissanayake, Ishara Ranathunga, et al.
Stroke|December 29, 2018
Canagliflozin and Stroke in Type 2 Diabetes MellitusZien Zhou, Richard I Lindley, Karin Rådholm, et al.
Diabetes Care|January 27, 2011
Monitoring of Individual Needs in Diabetes (MIND): baseline data from the Cross-National Diabetes Attitudes, Wishes, and Needs (DAWN) MIND studyFrank J Snoek, Nancy Y A Kersch, Ebbe Eldrup, et al.
Diabetes Care|July 28, 2012
Monitoring of Individual Needs in Diabetes (MIND)-2: follow-up data from the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) MIND studyFrank J Snoek, Nancy Y A Kersch, Ebbe Eldrup, et al.
Circulation|June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Cardiovascular Research|April 7, 2021
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trialJie Yu, Jingwei Li, Phillip J Leaver, et al.
Nature|November 23, 2007
Grand challenges in chronic non-communicable diseasesAbdallah S Daar, Peter A Singer, Deepa Leah Persad, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 24, 2020
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Plos One|June 14, 2014
Evaluation of common type 2 diabetes risk variants in a South Asian population of Sri Lankan descentNeelam Hassanali, N Maneka G De Silva, Neil Robertson, et al.
Diabetologia|May 15, 2020
Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literaturePrasad Katulanda, Harsha A Dissanayake, Ishara Ranathunga, et al.
Stroke|December 29, 2018
Canagliflozin and Stroke in Type 2 Diabetes MellitusZien Zhou, Richard I Lindley, Karin Rådholm, et al.
Diabetes Care|January 27, 2011
Monitoring of Individual Needs in Diabetes (MIND): baseline data from the Cross-National Diabetes Attitudes, Wishes, and Needs (DAWN) MIND studyFrank J Snoek, Nancy Y A Kersch, Ebbe Eldrup, et al.
Diabetes Care|July 28, 2012
Monitoring of Individual Needs in Diabetes (MIND)-2: follow-up data from the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) MIND studyFrank J Snoek, Nancy Y A Kersch, Ebbe Eldrup, et al.
Circulation|June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Cardiovascular Research|April 7, 2021
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trialJie Yu, Jingwei Li, Phillip J Leaver, et al.
Nature|November 23, 2007
Grand challenges in chronic non-communicable diseasesAbdallah S Daar, Peter A Singer, Deepa Leah Persad, et al.
Pageof 12